Antibody-drug conjugate · Kills target cells, directed at receptor tyrosine kinase-like orphan receptor 2 (ROR2) · developed by BioAtla
Ozuriftamab vedotin is an antibody-drug conjugate made of ozuriftamab, a conditionally active antibody against ROR2, linked to monomethyl auristatin E. The antibody becomes active only under the conditions of the tumor microenvironment, binds ROR2-expressing cancer cells, and is internalized to deliver the cytotoxic payload. It is being studied in ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04918186 | Phase 2 | Ovarian Cancer | Recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian Cancer